Heron Therapeutics, INC /DE/ 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Heron Therapeutics reports increased net product sales driven by strong acute care performance, despite a net loss and ongoing patent litigation for its oncology products.
NASDAQ
Heron Therapeutics details its financial performance for 2024, highlighting product sales growth and ongoing legal battles over key patents.
NASDAQ
Heron Therapeutics' 2023 10-K filing highlights a year of commercial expansion, strategic partnerships, and cost-saving measures, alongside ongoing challenges in a competitive market.